Purpose: To compare the short-term outcome of dental implant therapy in a group of organ transplant patients with that of a control group.

Materials And Methods: The study population included consecutive organ transplant patients and consecutive normal (healthy) subjects as controls. Two films were taken of all patients: one at baseline (implant placement) and one after 3 months of healing. All radiographs were analyzed twice (15 days apart) blindly by two independent trained radiologists. Crestal bone level (CBL) was measured, defined as the perpendicular distance from the reference point on the implant to the first visible apical bone-to-implant contact.

Results: The study population included 10 organ transplant patients (eight hearts, two livers) and 10 control patients, who received 20 and 12 submerged dental implants, respectively. At the 3-month follow-up visit, no implants showed any exposed cover screws. CBL increased in both groups, without any significant difference between the groups (CBL increased from 0.08±0.09 mm to 0.28±0.20 mm in transplant patients and from 0.11±0.16 mm to 0.42±0.32 mm in controls). Multiple analysis of variance showed that the mean bone loss of 0.21±0.18 mm observed in the group of transplant patients was not statistically different from that (0.32±0.25 mm) seen in the control group and was not influenced by any of the variables considered.

Conclusions: The present pilot study seems to indicate that the bone response around submerged dental implants in immunocompromised organ transplant patients does not differ from that observed in control patients and that this particular population of patients may be successfully rehabilitated with dental implants.

Download full-text PDF

Source

Publication Analysis

Top Keywords

transplant patients
28
organ transplant
20
dental implants
12
patients
11
bone response
8
response submerged
8
study population
8
population included
8
control patients
8
submerged dental
8

Similar Publications

Association Between Language, Interpreter Use, and Pediatric Surgical Outcomes.

J Pediatr Surg

January 2025

Division of Pediatric General and Thoracic Surgery, Seattle Children's Hospital, 4800 Sand Point Way NE, Seattle, WA 98105, USA; Department of Surgery, University of Washington, Box 356410, 1959 NE Pacific St, Seattle, WA 98195, USA.

Background: Inequities exist in pediatric surgical outcomes. Differential outcomes have been identified across racial groups, geography, and socioeconomic standing. However, the association between preferred language, interpreter use, and surgical outcomes is not well-studied in pediatric surgical literature.

View Article and Find Full Text PDF

Background Aims: Patients with hepatocellular carcinoma (HCC) meeting UNOS-downstaging (DS) criteria have excellent post-liver transplantation (LT) outcomes. Studies on HCC beyond UNOS-DS criteria ("All-comers" (AC)) have been limited by small sample size and short follow-up time, prompting this analysis.

Approach Results: 326 patients meeting UNOS-DS and 190 meeting AC criteria from 9 LT centers across 5 UNOS regions were enrolled from 2015 to 2023 and prospectively followed.

View Article and Find Full Text PDF

How I Treat Higher-Risk MDS.

Blood

January 2025

H. Lee Moffitt Cancer Center, Tampa, Florida, United States.

Myelodysplastic syndromes/neoplasms (MDS) are a widely heterogenous group of myeloid malignancies characterized by morphologic dysplasia, a defective hematopoiesis, and recurrent genetic abnormalities. The original and revised International Prognostic Scoring Systems (IPSS) have been used to risk-stratify patients with MDS to guide treatment strategies. In higher-risk MDS, the therapeutic approach is geared toward delaying leukemic transformation and prolonging survival.

View Article and Find Full Text PDF

The multicenter, phase III GMMG ReLApsE trial (EudraCT-No:2009-013856-61) randomized relapsed and/or refractory multiple myeloma (RRMM) patients equally to lenalidomide/dexamethasone (LEN/DEX, 25mg days 1-21/40mg weekly, 4-week cycles) re-induction, salvage high dose chemotherapy (sHDCT, melphalan 200mg/m2), autologous stem cell transplantation (ASCT) and LEN maintenance (10mg/day; transplant arm, n=139) versus continuous LEN/DEX (control arm, n=138). Ninety-four percent of patients had received frontline HDCT/ASCT. We report an updated analysis of survival endpoints with a median follow-up of 99 months.

View Article and Find Full Text PDF

In unrelated allogeneic hematopoietic cell transplantation (allo-HCT), older and/or HLA-mismatched donors are known risk factors for survival outcomes. In healthy individuals, cytomegalovirus (CMV) seropositivity is associated with impaired adaptive immune systems. We assessed whether the adverse effects of donor risk factors are influenced by the donor CMV serostatus.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!